The Current IL-4 and IL-13 Product Landscape in 2026
IL-4 and IL-13-targeted therapy has evolved into a broader, more structurally complex market than it was just a few years ago. The field remains concentrated around dupilumab, while selective IL-13 antibodies and a China-based IL-4Rα entrant are building narrower but increasingly important positions.